Treatment challenges in the management of difficult-to-treat gram-positive infections : A consensus view apropos therapeutic role of novel anti-MRSA antibiotics, levonadifloxacin (IV) and alalevonadifloxacin (oral)
Copyright © 2024 Indian Association of Medical Microbiologists. Published by Elsevier B.V. All rights reserved..
PURPOSE: Treatment of antibiotic-resistant Gram-positive infections (GPIs), including methicillin-resistant Staphylococcus aureus (MRSA) is becoming increasingly difficult, particularly in patients with multiple co-morbidities who require antibiotics with greater safety and a consistent pharmacokinetic/pharmacodynamic (PK/PD) profile. Such difficult-to-treat GPIs are often associated with poor outcomes, extended hospital stay and increased expenditure. This can be partly attributed to the limited safety and aberrant PK/PD profile of existing anti-MRSA antibiotics. In this context, intravenous levonadifloxacin and its oral prodrug alalevonadifloxacin are novel anti-MRSA antibiotics that have significant advantages over conventional anti-Gram-positive antibiotics. The purpose of this paper was to generate a consensus on the optimal use of levonadifloxacin and alalevonadifloxacin for tackling resistant Gram-positive infections in patients with multiple co-morbidities.
METHOD: Using a modified Delphi approach that combines critical appraisal of evidence and expert opinion, therapeutic use of levonadifloxacin and alalevonadifloxacin in various clinical scenarios and specific unmet conditions was deliberated. Fifteen expert members from medicine, critical-care, emergency, microbiology, and intensive-care disciplines participated and voted on 11 pre-conceived statements. When there was at least 70 % agreement, a consensus was reached.
RESULTS: Following the voting, agreements were reached on 10 out of the 11 statements. Broadly, a consensus was reached in defining the therapeutic role of levonadifloxacin and alalevonadifloxacin in the treatment of various clinical indications involving resistant Gram-positive pathogens, including MRSA, in patients with co-morbidities, such as co-existing or increased risk for kidney dysfunction or hepatic disease and/or immunosuppression; also, in therapeutically challenging conditions caused by Gram-positive bacteria such as bacteraemia, bone and joint infection, diabetic foot infection, febrile neutropenia, and hospital-acquired pneumonia.
CONCLUSIONS: This consensus supports the therapeutic use of levonadifloxacin and alalevonadifloxacin in the treatment of antibiotic-resistant GPIs, including those caused by MRSA and certain polymicrobial infections, in patients with multiple co-morbidities requiring drug with adequate safety and consistent efficacy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:47 |
|---|---|
| Enthalten in: |
Indian journal of medical microbiology - 47(2024) vom: 20. Jan., Seite 100528 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Saseedharan, Sanjith [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
8WHH66L098 |
|---|
| Anmerkungen: |
Date Completed 19.03.2024 Date Revised 19.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ijmmb.2024.100528 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367187817 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367187817 | ||
| 003 | DE-627 | ||
| 005 | 20240319232459.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240117s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ijmmb.2024.100528 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1336.xml |
| 035 | |a (DE-627)NLM367187817 | ||
| 035 | |a (NLM)38228227 | ||
| 035 | |a (PII)S0255-0857(24)00003-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Saseedharan, Sanjith |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Treatment challenges in the management of difficult-to-treat gram-positive infections |b A consensus view apropos therapeutic role of novel anti-MRSA antibiotics, levonadifloxacin (IV) and alalevonadifloxacin (oral) |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.03.2024 | ||
| 500 | |a Date Revised 19.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 Indian Association of Medical Microbiologists. Published by Elsevier B.V. All rights reserved. | ||
| 520 | |a PURPOSE: Treatment of antibiotic-resistant Gram-positive infections (GPIs), including methicillin-resistant Staphylococcus aureus (MRSA) is becoming increasingly difficult, particularly in patients with multiple co-morbidities who require antibiotics with greater safety and a consistent pharmacokinetic/pharmacodynamic (PK/PD) profile. Such difficult-to-treat GPIs are often associated with poor outcomes, extended hospital stay and increased expenditure. This can be partly attributed to the limited safety and aberrant PK/PD profile of existing anti-MRSA antibiotics. In this context, intravenous levonadifloxacin and its oral prodrug alalevonadifloxacin are novel anti-MRSA antibiotics that have significant advantages over conventional anti-Gram-positive antibiotics. The purpose of this paper was to generate a consensus on the optimal use of levonadifloxacin and alalevonadifloxacin for tackling resistant Gram-positive infections in patients with multiple co-morbidities | ||
| 520 | |a METHOD: Using a modified Delphi approach that combines critical appraisal of evidence and expert opinion, therapeutic use of levonadifloxacin and alalevonadifloxacin in various clinical scenarios and specific unmet conditions was deliberated. Fifteen expert members from medicine, critical-care, emergency, microbiology, and intensive-care disciplines participated and voted on 11 pre-conceived statements. When there was at least 70 % agreement, a consensus was reached | ||
| 520 | |a RESULTS: Following the voting, agreements were reached on 10 out of the 11 statements. Broadly, a consensus was reached in defining the therapeutic role of levonadifloxacin and alalevonadifloxacin in the treatment of various clinical indications involving resistant Gram-positive pathogens, including MRSA, in patients with co-morbidities, such as co-existing or increased risk for kidney dysfunction or hepatic disease and/or immunosuppression; also, in therapeutically challenging conditions caused by Gram-positive bacteria such as bacteraemia, bone and joint infection, diabetic foot infection, febrile neutropenia, and hospital-acquired pneumonia | ||
| 520 | |a CONCLUSIONS: This consensus supports the therapeutic use of levonadifloxacin and alalevonadifloxacin in the treatment of antibiotic-resistant GPIs, including those caused by MRSA and certain polymicrobial infections, in patients with multiple co-morbidities requiring drug with adequate safety and consistent efficacy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Alalevonadifloxacin | |
| 650 | 4 | |a Consensus | |
| 650 | 4 | |a Levonadifloxacin | |
| 650 | 4 | |a MRSA | |
| 650 | 4 | |a Resistant gram-positive | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 650 | 7 | |a levonadifloxacin |2 NLM | |
| 650 | 7 | |a 8WHH66L098 |2 NLM | |
| 650 | 7 | |a Fluoroquinolones |2 NLM | |
| 650 | 7 | |a Quinolones |2 NLM | |
| 650 | 7 | |a Quinolizines |2 NLM | |
| 700 | 1 | |a Dubey, Dilip |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Ratender Kumar |e verfasserin |4 aut | |
| 700 | 1 | |a Zirpe, Kapil |e verfasserin |4 aut | |
| 700 | 1 | |a Choudhuri, Anirban Hom |e verfasserin |4 aut | |
| 700 | 1 | |a Mukherjee, Dip Narayan |e verfasserin |4 aut | |
| 700 | 1 | |a Gupta, Neha |e verfasserin |4 aut | |
| 700 | 1 | |a Sahasrabudhe, Shrikant |e verfasserin |4 aut | |
| 700 | 1 | |a Soni, Sachin |e verfasserin |4 aut | |
| 700 | 1 | |a Kulkarni, Sudhir |e verfasserin |4 aut | |
| 700 | 1 | |a Walse, Prashant |e verfasserin |4 aut | |
| 700 | 1 | |a Vora, Agam Chandravadan |e verfasserin |4 aut | |
| 700 | 1 | |a Thomas, Jessy |e verfasserin |4 aut | |
| 700 | 1 | |a Tayade, Ashwini |e verfasserin |4 aut | |
| 700 | 1 | |a Bhadarke, Girish |e verfasserin |4 aut | |
| 700 | 1 | |a Kishore, Kamal |e verfasserin |4 aut | |
| 700 | 1 | |a Paliwal, Yashesh |e verfasserin |4 aut | |
| 700 | 1 | |a Patil, Pratik |e verfasserin |4 aut | |
| 700 | 1 | |a Reddy, Pavan Kumar |e verfasserin |4 aut | |
| 700 | 1 | |a Nagvekar, Vasant |e verfasserin |4 aut | |
| 700 | 1 | |a Veeraraghavan, Balaji |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Indian journal of medical microbiology |d 1996 |g 47(2024) vom: 20. Jan., Seite 100528 |w (DE-627)NLM086732056 |x 1998-3646 |7 nnns |
| 773 | 1 | 8 | |g volume:47 |g year:2024 |g day:20 |g month:01 |g pages:100528 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ijmmb.2024.100528 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 47 |j 2024 |b 20 |c 01 |h 100528 | ||